Pier Capital LLC Has $9.37 Million Position in Repligen Co. (NASDAQ:RGEN)

Pier Capital LLC raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 65,109 shares of the biotechnology company’s stock after acquiring an additional 766 shares during the quarter. Repligen makes up 1.3% of Pier Capital LLC’s portfolio, making the stock its 22nd largest holding. Pier Capital LLC’s holdings in Repligen were worth $9,372,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the third quarter worth approximately $37,000. Quarry LP raised its stake in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC grew its position in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 129 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on RGEN shares. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Finally, Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $178.64.

Repligen Stock Performance

Shares of Repligen stock opened at $145.15 on Tuesday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $198.00. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $8.15 billion, a PE ratio of -284.61, a PEG ratio of 4.54 and a beta of 0.95. The stock’s fifty day simple moving average is $155.91 and its 200 day simple moving average is $148.40.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, research analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.